Trump Administration Closes Drug Pricing Negotiation Loophole

The Trump administration is closing a loophole that allowed drugmakers to avoid Medicare price negotiations by adding active ingredients to existing drugs, and is codifying drug price rules. This structurally tightens the Medicare negotiation framework, removing an evasion mechanism that pharmaceutical companies had been using.

2 effects · 3 potentially affected companies · The full cascade analysis is part of the Pro plan. Create free account

Closing this loophole removes a structural escape valve that large-molecule and reformulated-drug manufacturers had used to avoid IRA-mandated Medicare price negotiations. Drugmakers with pipelines built around incremental reformulations of existing therapies face the most direct negative impact, as their strategy to reset negotiation timelines is now foreclosed. Innovators with genuinely novel mechanisms of action are relatively insulated, as the rule targets reformulation gaming rather than true new drugs. Generic and biosimilar manufacturers may benefit modestly, as branded reformulations that previously extended market exclusivity face greater pricing pressure. The codification of rules adds regulatory certainty for hospital systems and pharmacy benefit managers on the buyer side.